A single-centre, open, two-way cross-over, comparative study of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in patients with symptoms of GERD
Study identifier:SH-QBE-0091
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A single-centre, open, two-way cross-over, comparative study of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in patients with symptoms of GERD
Medical condition
gastrointestinal diseases
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 2001
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
